Robert More Biography and Net Worth

Director of Tyra Biosciences

Robert More is a Managing Director at Alta Partners, a healthcare focused venture capital firm. Bob currently manages investments in and serves on the board of Affinivax, eGenesis, Qihan Biopharmaceuticals, and Vir Biotechnology (NASDAQ:VIR). He was a founding board member of the Kauffman Fellows Program and is on the board of BIO (Biotechnology Innovation Organization). Before joining Alta, Bob was a Senior Advisor for the Bill and Melinda Gates Foundation. Prior to that, Bob spent 5 years as a General Partner at Frazier Healthcare Ventures and 13 years at Domain Associates. He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.

What is Robert J. More's net worth?: The estimated net worth of Robert J. More is at least $116.53 million as of December 19th, 2025. More owns 3,823,425 shares of Tyra Biosciences stock worth more than $116,526,524 as of February 3rd. This net worth evaluation does not reflect any other assets that More may own. Learn More about Robert J. More's net worth.
How do I contact Robert J. More?: The corporate mailing address for More and other Tyra Biosciences executives is 2656 STATE STREET, CARLSBAD CA, 92008. Tyra Biosciences can also be reached via phone at 619-728-4760 and via email at [email protected].. Learn More on Robert J. More's contact information.
Has Robert J. More been buying or selling shares of Tyra Biosciences?: Robert J. More has not been actively trading shares of Tyra Biosciences over the course of the past ninety days. Most recently, Robert J. More sold 10,000 shares of the business's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $25.00, for a transaction totalling $250,000.00. Following the completion of the sale, the director now directly owns 3,823,425 shares of the company's stock, valued at $95,585,625. Learn More on Robert J. More's trading history.
Who are Tyra Biosciences' active insiders?: Tyra Biosciences' insider roster includes Daniel Bensen (COO), Alan Fuhrman (CFO), Todd Harris (CEO), Gilla Kaplan (Director), and Robert More (Director). Learn More on Tyra Biosciences' active insiders.
Are insiders buying or selling shares of Tyra Biosciences?: In the last twelve months, insiders at the sold shares 8 times. They sold a total of 323,664 shares worth more than $5,951,813.37. The most recent insider tranaction occured on December, 19th when Director Robert J More sold 10,000 shares worth more than $250,000.00. Insiders at Tyra Biosciences own 15.2% of the company. Learn More about insider trades at Tyra Biosciences.
Information on this page was last updated on 12/19/2025.

Robert J. More Insider Trading History at Tyra Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/19/2025	Sell	10,000	$25.00	$250,000.00	3,823,425
11/21/2025	Sell	246,871	$20.25	$4,999,137.75	3,833,425

Robert J. More Buying and Selling Activity at Tyra Biosciences

Tyra Biosciences Company Overview

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Today's Range

Now: $30.48

$30.94

$32.37

50 Day Range

MA: $26.13

$20.81

$32.34

2 Week Range

Now: $30.48

$6.42

$32.44

Volume

339,477 shs

Average Volume

674,835 shs

Market Capitalization

$1.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07